Immunoprecipitation market seen reaching $4.13 billion by 2035

Market Research Future projects the global immunoprecipitation market will grow from $2.24 billion in 2024 to $4.13 billion by 2035, driven by genomics and proteomics research, chronic disease prevalence, and better assay technology. North America leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Immunoprecipitation is becoming more important in disease research, drug development and protein analysis. - Market growth reflects rising demand for tools that can isolate and study proteins, protein-DNA interactions and RNA-protein interactions. - The market is also benefiting from broader use of advanced diagnostics and precision medicine workflows.

What happened: - Market Research Future projected the global immunoprecipitation market will rise from $2.24 billion in 2024 to $4.13 billion by 2035. - The forecast implies a 5.71% compound annual growth rate from 2025 to 2035. - The report links the market expansion to research activity in genomics, proteomics and immunotherapy. - The report also cites growing chronic disease prevalence, including cancer and cardiovascular conditions, as a key driver. - A free sample is available here.

The details: - Reagents held the largest product share in 2024 at 54.7%. - Reagents include antibodies, agarose and magnetic beads, and buffers. - Kits are gaining demand because they offer standardized workflows for specific applications. - Individual protein immunoprecipitation isolates a single protein of interest. - Co-immunoprecipitation is used to study protein-protein interactions. - Chromatin immunoprecipitation is used to study protein-DNA interactions and epigenetic changes. - RNA immunoprecipitation is used to study RNA-protein interactions. - Academic and research institutes remain the largest end-user group. - Pharmaceutical and biotechnology companies are a major demand source for drug discovery and development. - Contract research organizations are expanding as outsourced research grows. - North America holds the largest regional share, supported by research infrastructure and NIH funding. - Europe ranks second, with Germany, the UK and France leading activity. - Asia-Pacific is expected to be the fastest-growing region, supported by healthcare investment and research capacity. - The report points to China’s Healthy China 2030 plan and India’s Biotechnology Industry Research Assistance Council as growth supports. - Key companies listed in the market include Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Abcam, Cell Signaling Technology, GenScript Biotech and Takara Bio. - The full report is available here.

Between the lines: - The market forecast signals that immunoprecipitation is shifting from a niche lab method to a core enabling technology for protein-centered research. - Advances in high-affinity antibodies, magnetic bead-based methods and mass spectrometry integration are improving assay performance. - AI and machine learning are increasingly relevant because proteomic datasets are becoming more complex. - The report suggests competition will remain active, with product launches, partnerships and acquisitions shaping share gains. - The market is described as moderately fragmented, which leaves room for multiple suppliers and specialized product lines.

What's next: - Growth opportunities include high-throughput immunoprecipitation kits for large studies. - Vendors are expected to expand AI-driven analytics to improve interpretation of assay data. - Companies may push further into emerging markets with localized product offerings. - Biotech partnerships are likely to remain a route for new product development. - The market’s 2035 outlook points to continued demand from research and diagnostics.